Significance of heparanase in cancer and inflammation

Cancer Microenvironment

Volumn 5, Issue 2, 2012, Pages 115-132

  Vlodavsky, Israel ^a   Beckhove, Phillip ^b   Lerner, Immanuel ^c   Pisano, Claudio ^d   Meirovitz, Amichai ^c   Ilan, Neta ^a   Elkin, Michael ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Sigma Tau SpA   (Italy)

Author keywords

Colitis; Colon carcinoma; Extracellular matrix; Heparan sulfate; Heparanase; Inflammation; Metastasis; Tumor associated macrophages; Tumor microenvironment

Indexed keywords

ENZYME INHIBITOR; GLYCOSIDASE; HEPARAN SULFATE; HEPARAN SULFATE DEGRADING ENDOGLYCOSIDASE; HEPARANASE; HEPARANASE INHIBITOR; HEPARIN; MIR 1258; OLIGOSACCHARIDE; PEPTIDE; PEPTIDE VACCINE; PG 545; PROTEOHEPARAN SULFATE; SST 0001; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; BRAIN METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL INVASION; CELL MICROENVIRONMENT; CELLS; COLITIS; COLON CARCINOGENESIS; COLON MUCOSA; DIABETIC NEPHROPATHY; DRUG DEVELOPMENT; DRUG TARGETING; ENTERITIS; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SYNTHESIS; EUKARYOTIC CELL; EXTRACELLULAR MATRIX; GLOMERULUS BASEMENT MEMBRANE; HEPARIN BINDING MOLECULE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; IONIZING RADIATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MACROPHAGE ACTIVATION; METASTASIS; METASTASIS POTENTIAL; MOLECULAR CLONING; MOLECULE; MYELOMA; NEOPLASM; NONHUMAN; PANCREAS CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RADIATION DOSE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; UPREGULATION;

EID: 84866351573     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-011-0082-7     Document Type: Review

References (212)

1. Vlodavsky I, Gospodarowicz D (1981) Respective roles of laminin and fibronectin in adhesion of human carcinoma and sarcoma cells. Nature 289:304-306
2. Vlodavsky I, Lui GM, Gospodarowicz D (1980) Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix versus plastic. Cell 19:607-616
3. Vlodavsky I (2001) Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells. Curr Protoc Cell Biol. Chapter 10:Unit 10.4
4. Kleinman HK, Martin GR (2005) Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 15:378-386
5. Xu R, Boudreau A, Bissell MJ (2009) Tissue architecture and function: dynamic reciprocity via extra- and intra-cellular matrices. Cancer Metastasis Rev 28:167-176
6. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I (1988) A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 130:393-400
7. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277:3904-3923
8. Iozzo RV, San Antonio JD (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108:349-355
9. Kjellen L, Lindahl U (1991) Proteoglycans: structures and interactions. Annu Rev Biochem 60:443-475
10. Bernfield M, Gotte M, Park PW et al (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777
11. Capila I, Linhardt RJ (2002) Heparin-protein interactions. Angew Chem Int Ed Engl 41:391-412
12. Lindahl U, Li JP (2009) Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol 276:105-159
13. Ogren S, Lindahl U (1975) Cleavage of macromolecular heparin by an enzyme from mouse mastocytoma. J Biol Chem 250:2690-2697
14. Thunberg L, Backstrom G, Wasteson A, Robinson HC, Ogren S, Lindahl U (1982) Enzymatic depolymerization of heparin-related polysaccharides. Substrate specificities of mouse mastocytoma and human platelet endo-beta-D- glucuronidases. J Biol Chem 257:10278-10282
15. Parish CR, Freeman C, Hulett MD (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471: M99-M108
16. Lerner I, Hermano E, Zcharia E et al (2011) Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 121:1709-1721
17. Li RW, Freeman C, Yu D et al (2008) Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 58:1590-1600
18. van den Hoven MJ, Rops AL, Bakker MA et al (2006) Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70:2100-2108
19. Lindahl U (1990) Biosynthesis of heparin. Biochem Soc Trans 18:803-805
20. Kreuger J, Spillmann D, Li JP, Lindahl U (2006) Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 174:323-327
21. Ledin J, Staatz W, Li JP et al (2004) Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem 279:42732-42741
22. Gray E, Mulloy B, Barrowcliffe TW (2008) Heparin and lowmolecular- weight heparin. Thromb Haemost 99:807-818
23. Lindahl U (2007) Heparan sulfate-protein interactions-a concept for drug design? Thromb Haemost 98:109-115
24. Fransson LA, Belting M, Cheng F, Jonsson M, Mani K, Sandgren S (2004) Novel aspects of glypican glycobiology. Cell Mol Life Sci 61:1016-1024
25. Cole GJ, Halfter W (1996) Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 3:359-371
26. Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67:609-652
27. Kramer KL, Yost HJ (2003) Heparan sulfate core proteins in cellcell signaling. Annu Rev Genet 37:461-484
28. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521-528
29. Simons M, Horowitz A (2001) Syndecan-4-mediated signalling. Cell Signal 13:855-862
30. Timpl R, Brown JC (1996) Supramolecular assembly of basement membranes. Bioessays 18:123-132
31. Hacker U, Nybakken K, Perrimon N (2005) Heparan sulphate proteoglycans: the sweet side of development. NatRev Mol Cell Biol 6:530-541
32. Sanderson RD (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Devel Biol 12:89-98
33. Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L, Kovalszky I (2002) Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 12:173-186
34. Belting M (2003) Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 28:145-151
35. Bashkin P, Doctrow S, Klagsbrun M, Svahn CM, Folkman J, Vlodavsky I (1989) Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28:1737-1743
36. Patel VN, Knox SM, Likar KM et al (2007) Heparanase cleavage of perlecan heparan sulfate modulates FGF10 activity during ex vivo submandibular gland branching morphogenesis. Development 134:4177-4186
37. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z (1991) Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biochem Sci 16:268-271
38. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D (1996) Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15:177-186
39. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I (2010) Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277:3890-3903
40. Ilan N, Elkin M, Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38:2018-2039
41. Levy-Adam F, Feld S, Cohen-Kaplan V et al (2010) Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem 285:28010-28019
42. McKenzie E, Tyson K, Stamps A et al (2000) Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 276:1170-1177
43. Vlodavsky I, Eldor A, Haimovitz-Friedman A et al (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12:112-127
44. Elkin M, Ilan N, Ishai-Michaeli R et al (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15:1661-1663
45. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N (2003) Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 308:885-891
46. McKenzie E, Young K, Hircock M et al (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373:423-435
47. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, Steinkuhler C (2004) Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43:1862-1873
48. Fux L, Ilan N, Sanderson RD, Vlodavsky I (2009) Heparanase: busy at the cell surface. Trends Biochem Sci 34:511-519
49. Hulett MD, Hornby JR, Ohms SJ et al (2000) Identification of active-site residues of the pro-metastatic endoglycosidase heparanase. Biochemistry 39:15659-15667
50. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H et al (2005) Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 280:13568-13575
51. Abboud-Jarrous G, Atzmon R, Peretz T et al (2008) Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283:18167-18176
52. Nakajima M, Irimura T, DiFerrante D, DiFerrante N, Nicolson GL (1983) Heparan sulfate degradation: relation to tumor invasion and metastatic properties of Mouse B 16 Melanoma sublines. Science 220:611-613
53. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirrmacher V (1983) Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis. Cancer Res 43:2704-2711
54. Cohen I, Pappo O, Elkin M et al (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 118:1609-1617
55. Lerner I, Baraz L, Pikarsky E et al (2008) Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 14:668-676
56. Edovitsky E, Elkin M, Zcharia E, Peretz T, Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96:1219-1230
57. Vreys V, David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11:427-452
58. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoteto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, Vlodavsky I, Zunino F (2011) J cell mol med (PMID: 21029368)
59. Vlodavsky I, Ilan N, Naggi A, Casu B (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13:2057-2073
60. Casu B, Guerrini M, Guglieri S et al (2004) Undersulfated and glycol-split heparins endowed with antiangiogenic activity. J Med Chem 47:838-848
61. Ferro V, Hammond E, Fairweather JK (2004) The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 4:693-702
62. McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151:1-14
63. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z (2006) Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13:2101-2111
64. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, Vlodavsky I (2006) Neoplasia 8:1055-1061
65. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N (2001) Clin Cancer Res 7(5):1299-1305
66. Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA, Xu X (2002) Surgery 132:326-333
67. Nagler R, Ben-Izhak O, Cohen-Kaplan V, Shafat I, Vlodavsky I, Akrish S, Ilan N (2007) Cancer 110:2732-2739
68. Tang W, Nakamura Y, Tsujimoto M, Sato M, Wang X, Kurozumi K, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (2002) Mod Pathol 15:593-598
69. Barash U, Cohen-Kaplan V, Arvatz G et al (2010) A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics. FASEB J 24:1239-1248
70. Doviner V, Maly B, Kaplan V et al (2006) Spatial and temporal heparanase expression in colon mucosa throughout the adenomacarcinoma sequence. Mod Pathol 19:878-888
71. Yang Y, Macleod V, Bendre M et al (2005) Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105:1303-1309
72. Zetser A, Bashenko Y, Miao H-Q, Vlodavsky I, Ilan N (2003) Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63:7733-7741
73. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z (1990) Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9:203-226
74. Witz IP (2008) Tumor-microenvironment interactions: dangerous liaisons. Adv Cancer Res 100:203-229
75. Ruoslahti E (1996) How cancer spreads. Sci Am 275:72-77
76. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411:375-379
77. Kessenbrock K, Plaks V,Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67
78. Mason SD, Joyce JA (2011) Proteolytic networks in cancer. Trends Cell Biol 21:228-237
79. Stupack DG, Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev Biol 64:207-238
80. Noel A, Jost M, Maquoi E (2008) Matrix metalloproteinases at cancer tumor-host interface. Sem Cell Dev Biol 19:52-60
81. Van Damme J, Struyf S, Opdenakker G (2004) Chemokineprotease interactions in cancer. Semin Cancer Biol 14:201-208
82. Gocheva V, Joyce JA (2007) Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6:60-64
83. Lankelma JM, Voorend DM, Barwari T et al (2010) Cathepsin L, target in cancer treatment? Life Sci 86:225-233
84. Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477:98-111
85. Bix G, Iozzo RV (2005) Matrix revolutions: "tails" of basementmembrane components with angiostatic functions. Trends Cell Biol 15:52-60
86. Purushothaman A, Chen L, Yang Y, Sanderson RD (2008) Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 283:32628-32636
87. Zcharia E, Jia J, Zhang X et al (2009) Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS ONE 4:e5181
88. Chen L, Sanderson RD (2009) Heparanase regulates levels of syndecan-1 in the nucleus. PLoS ONE 4(3):e4947
89. Paget S (1889) The distribution of a secondary growths in cancer of the breast. Lancet 133:571-583
90. Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70:5649-5669
91. Nicolson GL (1988) Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7:143-188
92. Kaplan RN, Psaila B, Lyden D (2006) Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev 25:521-529
93. Kaplan RN, Rafii S, Lyden D (2006) Preparing the "soil": the premetastatic niche. Cancer Res 66:11089-11093
94. Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1- positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827
95. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
96. Franco OE, Shaw AK, Strand DW, Hayward SW (2010) Cancer associated fibroblasts in cancer pathogenesis. Sem Cell Dev Biol 21:33-39
97. Shimoda M, Mellody KT, Orimo A (2010) Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Sem cell Dev Biol 221:19-25
98. Bhowmick NA, Chytil A, Plieth D et al (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851
99. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332-337
100. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6:392-401
101. Erez N, Truitt M, Olson P, Arron ST, Hanahan D (2010) Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaBdependent manner. Cancer Cell 17:135-147
102. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883-899
103. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Cur Opin Immunol 22:231-237
104. Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263-266
105. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80:1183-1196
106. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71-78
107. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I, Elkin M (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107:3609-3616
108. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, Ilan N (2007) Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 20:8-14
109. Clevers H (2006) Colon cancer-understanding how NSAIDs work. N Engl J Med 354:761-763
110. Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759
111. Greten FR, Eckmann L, Greten TF et al (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitisassociated cancer. Cell 118:285-296
112. Popivanova BK, Kitamura K, Wu Y et al (2008) Blocking TNFalpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118:560-570
113. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S (1996) Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 39:87-92
114. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436
115. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798-809
116. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694-702
117. Zcharia E, Metzger S, Chajek-ShaulL T et al (2004) Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 18:252-263
118. Mahida YR (2000) The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6:21-33
119. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK (2008) Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14:4280-4288
120. Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344-1367
121. Krieglstein CF, Cerwinka WH, Sprague AG et al (2002) Collagenbinding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest 110:1773-1782
122. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392
123. Brunn GJ, Bungum MK, Johnson GB, Platt JL (2005) Conditional signaling by Toll-like receptor 4. FASEB J 19:872-874
124. Fukata M, Chen A, Vamadevan AS et al (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133:1869-1881
125. Fukata M, Hernandez Y, Conduah D et al (2009) Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis 15:997-1006
126. Kumar V, Abbas A, Fausto N, (eds) (2005) Pathologic basis of disease: Elsevier Saunders
127. de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, Hulett MD (2005) Early Growth Response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 280:35136-35147
128. Subbaramaiah K, Yoshimatsu K, Scherl E et al (2004) Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem 279:12647-12658
129. Fiebiger E, Maehr R, Villadangos J et al (2002) Invariant chain controls the activity of extracellular cathepsin L. J Exp Med 196:1263-1269
130. Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3:521-533
131. Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM (2008) Molecular targeted therapies for pancreatic cancer. Am J Surg 196:430-441
132. Raimondi S, Maisonneuve P, Lowenfels AB (2009) Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6:699-708
133. Shaib YH, Davila JA, El-Serag HB (2006) The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther 24:87-94
134. Muller MW, Friess H, Koninger J et al (2008) Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg 195:221-228
135. Network NCC (2008) NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. v.1
136. Cohen SJ, Dobelbower R Jr, Lipsitz S et al (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62:1345-1350
137. Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210
138. Camphausen K, Moses MA, Beecken W-D, Khan MK, Folkman J, O'Reilly MS (2001) Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61:2207-2211
139. Kaliski A, Maggiorella L, Cengel KA et al (2005) Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 4:1717-1728
140. Madani I, De Neve W, Mareel M (2008) Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer 95:292-300
141. Ohuchida K, Mizumoto K, Murakami M et al (2004) Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64:3215-3222
142. Park CM, Park MJ, Kwak HJ et al (2006) Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptormediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66:8511-8519
143. Qian L-W, Mizumoto K, Urashima T et al (2002) Radiationinduced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res 8:1223-1227
144. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61:2744-2750
145. Meirovitz A, Hermano E, Lerner I et al (2011) Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 71:2772-2780
146. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A, Buchler MW (2001) Cancer Res 61:4655-4659
147. Quiros RM, Rao G, Plate J et al (2006) Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer 106:532-540
148. Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H, Mossner J, Wittekind C, Caca K (2002) Br J Cancer 86:1270-1275
149. Hoffmann AC, Mori R, Vallbohmer D et al (2008) High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 12:1674-1681
150. de Mestre AM, Khachigian LM, Santiago FS, Staykova MA, Hulett MD (2003) Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J Biol Chem 278:50377-50385
151. de Mestre AM, Staykova MA, Hornby JR, Willenborg DO, Hulett MD (2007) Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J Leukoc Biol 82:1289-1300
152. Srinivasan R, Mager GM, Ward RM, Mayer J, Svaren J (2006) NAB2 represses transcription by interacting with the CHD4 subunit of the nucleosome remodeling and deacetylase (NuRD) complex. J Biol Chem 281:15129-15137
153. Casu B, Guerrini M, Torri G (2004) Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Des 10:939-949
154. Casu B, Vlodavsky I, Sanderson RD (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36:195-203
155. Naggi A, Casu B, Perez M et al (2005) Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280:12103-12113
156. Chung SI, Seong J, Park YN, Kim WW, Oh HJ, Han KH. Identification of proteins indicating radiation-induced hepatic toxicity in cirrhotic rats. J Rsd Res 51:643-650
157. Iriyama S, Matsunaga Y, Takahashi K, Matsuzaki K, Kumagai N, Amano S (2011) Activation of heparanase by ultraviolet B irradiation leads to functional loss of basement membrane at the dermal-epidermal junction in human skin. Arch Dermatol Res 303:253-261
158. Chen T, Tang XD, Wan Y et al (2008) HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. Neoplasia 10:977-986
159. Tang W, Nakamura Y, Tsujimoto M et al (2002) Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol 15:593-598
160. Tang XD, Liang GP, Li C et al (2010) Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice. Cancer Immunol Immunother 59:1041-1047
161. Wang GZ, Tang XD, Lu MH, et al (2011) Multiple antigenic peptides of human heparanase elicit a much more potent immune response against tumors. Canc Prev Res (PMID: 21505182)
162. Beckhove P, Feuerer M, Dolenc M et al (2004) Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 114:67-76
163. Feuerer M, Beckhove P, Garbi N et al (2003) Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 9:1151-1157
164. Khazaie K, Prifti S, Beckhove P et al (1994) Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 91:7430-7434
165. Schirrmacher V, Feuerer M, Fournier P, Ahlert T, Umansky V, Beckhove P (2003) T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 9:526-534
166. Bai L, Beckhove P, Feuerer M et al (2003) Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer 103:73-83
167. Schmitz-Winnenthal FH, Volk C, Z'Graggen K et al (2005) High frequencies of functional tumor-reactive Tcells in bone marrow and blood of pancreatic cancer patients. Cancer Res 65:10079-10087
168. Wagner P, Koch M, Nummer D et al (2008) Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol 15:2310-2317
169. Schuetz F, Ehlert K, Ge Y et al (2008) Treatment of advanced metastasized breast cancer with bone marrow-derived tumourreactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 58:887-900
170. Sommerfeldt N, Beckhove P, Ge Y et al (2006) Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 66:7716-77123
171. Bonertz A, Weitz J, Pietsch DH et al (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119:3311-3321
172. Schuetz F, Ehlert K, Ge Y et al (2009) Treatment of advanced metastasized breast cancer with bone marrow-derived tumourreactive memory T cells: a pilot clinical study. Cancer Immunol Immunother 58:887-900
173. Levy-Adam F, Ilan N, Vlodavsky I (2010) Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 20:153-160
174. Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I, Ilan N (2008) Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS ONE 3: e2319
175. Kim MY, Oskarsson T, Acharyya S et al (2009) Tumor selfseeding by circulating cancer cells. Cell 139:1315-1326
176. Leung CT, Brugge JS (2009) Tumor self-seeding: bidirectional flow of tumor cells. Cell 139:1226-1228
177. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D (2005) A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24:4037-4051
178. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O (2000) Am J Pathol 157(4):1167-1175
179. Brun R, Naroditsky I, Waterman M et al (2009) Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. Mod Pathol 22:1548-1554
180. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123:2566-2573
181. Buczek-Thomas JA, Hsia E, Rich CB, Foster JA, Nugent MA (2008) Inhibition of histone acetyltransferase by glycosaminoglycans. J Cell Biochem 105:108-120
182. Kovalszky I, Dudas J, Olah-Nagy J et al (1998) Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor. Mol Cell Biochem 183:11-23
183. Ohkawa T, Naomoto Y, Takaoka M et al (2004) Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest 84:1289-1304
184. Schubert SY, Ilan N, Shushy M, Ben-Izhak O, Vlodavsky I, Goldshmidt O (2004) Human heparanase nuclear localization and enzymatic activity. Lab Invest 84:535-544
185. Kobayashi M, Naomoto Y, Nobuhisa T et al (2006) Heparanase regulates esophageal keratinocyte differentiation through nuclear translocation and heparan sulfate cleavage. Differentiation 74:235-243
186. Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD (2011) Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem PMID: 21757697
187. Szymczak M, Kuzniar J, Klinger M (2010) The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp 58:45-56
188. van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, van der Vlag J (2007) Heparanase in glomerular diseases. Kidney Int 72:543-548
189. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA (2004) Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. J Am Soc Nephrol 15:68-78
190. Levidiotis V, Kanellis J, Ierino FL, Power DA (2001) Increased expression of heparanase in puromycin aminonucleoside nephrosis. Kidney Int 60:1287-1296
191. Levidiotis V, Freeman C, Tikellis C, Cooper ME, Power DA (2005) Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology 10:167-173
192. Ritchie JP, Ramani VC, Ren Y et al (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17:1382-1393
193. Higgins WJ, Fox DM, Kowalski PS, Nielsen JE, Worrall DM (2010) Heparin enhances serpin inhibition of the cysteine protease cathepsin L. J Biol Chem 285:3722-3729
194. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I (2011) The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 30:253-268
195. Dredge K, Hammond E, Handley P et al (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent antitumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104:635-642
196. Zhang L, Sullivan PS, Goodman JC, Gunaratne PH, Marchetti D (2011) MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 71:645-654
197. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M (2001) Int J Cancer 95:295-301
198. Gohji K, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, Nakajima M (2001) J Urol 166:1286-1290
199. Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y (2003) Ann Oncol 14:1505-1510
200. Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, Gunduz M, Shirakawa Y, Yamatsuji T, Haisa M, Matsuoka J, Tsujigiwa H, Nagatsuka H, Nakajima M, Tanaka N (2005) J Cancer Res Clin Oncol 131:229-237
201. Sato T, Yamaguchi A, Goi T, Hirono Y, Takeuchi K, Katayama K, Matsukawa S (2004) J Surg Oncol 87:174-181
202. Watanabe M, Aoki Y, Kase H, Tanaka K (2003) Gynecol Obstet Invest 56:77-82
203. Endo K, Maejara U, Baba H, Tokunaga E, Koga T, Ikeda Y, Toh Y, Kohnoe S, Okamura T, Nakajima M, Sugimachi K (2001) Anticancer Res 21:3365-3369
204. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujiwara T, Gunduz M, Nagatsuka H, Nakajima M, Tanaka N, Haisa M (2003) Lab Invest 83:613-622
205. Takahashi H, Ebihara S, Okazaki T, Suzuki S, Asada M, Kubo H, Sasaki H (2004) Lung Canc (Amsterdam, Netherlands) 45: 207-214
206. Cohen E, Doweck I, Naroditsky I, Ben-Izhak O, Kremer R, Best LA, Vlodavsky I, Ilan N (2008) Cancer 113:1004-1011
207. Kelly T, Miao H-Q, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD (2003) Cancer Res 63:8749-8756
208. Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I, Ben-Izhak O (2006) Histopathology 49:188-193
209. Zheng LD, Tong QS, Tang ST, Du ZY, Liu Y, Jiang GS, Cai JB (2009) World J Pediatr 5:206-210
210. Kim AW, Xu X, Hollinger EF, Gattuso P, Godellas CV, Prinz RA (2002) J Gastrointest Surg 6:167-172
211. Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, Kosaka T, Mukai M, Nakajima M, Okada Y (2008) Clin Cancer Res 14:6055-6061
212. Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I, Nagler R (2006) Neoplasia 8:879-884